Compare OSW & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | CLDX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2019 | 1995 |
| Metric | OSW | CLDX |
|---|---|---|
| Price | $24.74 | $34.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $27.00 | ★ $44.50 |
| AVG Volume (30 Days) | 624.6K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $961,001,000.00 | $12,743,000.00 |
| Revenue This Year | $7.49 | $111.39 |
| Revenue Next Year | $8.52 | $235.85 |
| P/E Ratio | $35.79 | ★ N/A |
| Revenue Growth | 7.37 | ★ 87.78 |
| 52 Week Low | $16.16 | $17.87 |
| 52 Week High | $25.25 | $35.29 |
| Indicator | OSW | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 65.05 |
| Support Level | $20.62 | $24.70 |
| Resistance Level | N/A | $34.52 |
| Average True Range (ATR) | 0.68 | 1.46 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 84.82 | 81.67 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.